EUVIMEDEUVIMED entdecken
Crossref

16-mer hypocretin-1/orexin-A in cerebrospinal fluid to diagnose narcolepsy

Jerome Vialaret, Christophe Hirtz, Manuela Lotierzo, Lucie Barateau, Jean Paul Cristol, Jerome Tanty, Isabelle Jaussent iD, Sylvain Lehmann, Yves Dauvilliers iD

SLEEPJ · 2025

DOI: 10.1093/sleep/zsaf237 ↗

Kurz gefasst

Fachartikel in der Zeitschrift SLEEPJ, 2025. Verfasst von Jerome Vialaret und 8 weiteren Autor:innen. Beteiligte Einrichtung: LBPC-PPC, University of Montpellier, IRMB, CHU de Montpellier, Montpellier, France. Hauptthemen laut MEDLINE: Orexins, Narcolepsy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: French National Research Agency, Foundation pour la Recherche Médicale (FRM), European Community.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Study Objectives Cerebrospinal fluid (CSF) hypocretin-1/orexin-A quantification via radioimmunoassay (RIA) is used for diagnosing narcolepsy type 1(NT1), but its limitations require alternative methods. Using liquid chromatography–mass spectrometry (LC–MS), this study aimed to 1) fully characterize CSF orexin-A fragments detected by the gold standard RIA method, and 2) assess diagnostic relevance of measuring the most prevalent fragment, a 16-mer, in patients with NT1, narcolepsy type 2 (NT2), idiopathic hypersomnia (IH), and nonspecified hypersomnolence (NSH).

Methods

CSF samples were analyzed using RIA and LC–MS in patients with hypersomnolence disorders evaluated at the French Narcolepsy National Reference Center. Fractionation techniques isolated orexin-A and its fragments, which were identified via targeted MS. Statistical analysis compared LC–MS performance against RIA.

Results

CSF samples from 115 patients (54.8% females, mean age 30.4 ± 15.8 years) including 52 with NT1, 6 NT2, 13 IH, and 44 NSH were analyzed by RIA and LC–MS. A 16-mer orexin-A fragment was identified and quantified by LC–MS, with lower levels in NT1. This fragment correlated strongly with RIA-measured orexin-A (r = 0.83, p < .0001) and demonstrated high sensitivity (98.1%) and specificity (85.7%) for diagnosis of NT1. Receiver operating characteristics analyses confirmed the high performance with an area under the curve of 0.975 and an optimal diagnostic cutoff of 10.67 pg/mL for LC–MS.

Conclusions

The 16-mer orexin-A peptide represents a promising biomarker that could in the future help in the diagnosis of central hypersomnolence disorders. The transition from RIA to LC–MS methods for the quantification of 16-mer orexin-A represents a critical advance toward improving diagnostic accuracy and understanding orexinergic dysfunction in sleep disorders.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OrexinsNarcolepsyHumansFemaleMaleAdultRadioimmunoassayChromatography, LiquidMiddle AgedMass SpectrometrySensitivity and SpecificityYoung AdultBiomarkersDisorders of Excessive Somnolence

Stichwörter der Autor:innen

diagnosisliquid chromatography–mass spectrometrynarcolepsyorexin/hypocretinradioimmunoassay

Substanzen

OrexinsBiomarkersHCRT protein, human

Autor:innen und Institutionen

  • LBPC-PPC, University of Montpellier, IRMB, CHU de Montpellier, Montpellier, France.
  • Institute of Neurosciences of Montpellier (INM), INSERM, Montpellier, France.
  • Laboratory of Biochemistry and Hormonology, Lapeyronie Hospital, CHU Montpellier, Montpellier, France.
  • Sleep-Wake Disorders Unit, Department of Neurology, Gui-de-Chauliac Hospital, CHU Montpellier, Montpellier, University of Montpellier, France.
  • National Reference Centre for Orphan Diseases, Narcolepsy, Idiopathic Hypersomnia, and Kleine-Levin Syndrome, Department of Neurology, Montpellier, France.

ORCID-Profile: Isabelle Jaussent, Yves Dauvilliers

Förderung

  • French National Research Agency
  • Foundation pour la Recherche Médicale (FRM)
  • European Community

Zitieren

APA

Vialaret, J., Hirtz, C., Lotierzo, M., Barateau, L., Cristol, J. P., Tanty, J., Jaussent, I., Lehmann, S., & Dauvilliers, Y. (2025). 16-mer hypocretin-1/orexin-A in cerebrospinal fluid to diagnose narcolepsy. SLEEPJ. https://doi.org/10.1093/sleep/zsaf237

Vancouver

Vialaret J, Hirtz C, Lotierzo M, Barateau L, Cristol JP, Tanty J, et al. 16-mer hypocretin-1/orexin-A in cerebrospinal fluid to diagnose narcolepsy. SLEEPJ. 2025. doi:10.1093/sleep/zsaf237

BibTeX
@article{Vialaret2025,
  author = {Vialaret, Jerome and Hirtz, Christophe and Lotierzo, Manuela and Barateau, Lucie and Cristol, Jean Paul and Tanty, Jerome and Jaussent, Isabelle and Lehmann, Sylvain and Dauvilliers, Yves},
  title = {16-mer hypocretin-1/orexin-A in cerebrospinal fluid to diagnose narcolepsy},
  journal = {SLEEPJ},
  year = {2025},
  doi = {10.1093/sleep/zsaf237}
}
Kostenlos starten →